Cross-species pharmacologic evaluation of plasmin as a direct-acting thrombolytic agent: Ex vivo evaluation for large animal model development

Journal of Vascular and Interventional Radiology

Volumn 16, Issue 3, 2005, Pages 369-377

  Landskroner, Kyle ^a,b   Olson, Neil ^a   Jesmok, Gary ^b  

^a NORTH CAROLINA STATE UNIVERSITY   (United States)

^b BAYER CORPORATION   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

FIBRIN; PLASMIN; TISSUE PLASMINOGEN ACTIVATOR;

ARTICLE; BLOOD CLOT LYSIS; CONCENTRATION RESPONSE; CONTROLLED STUDY; COW; DRUG EFFECT; DRUG EFFICACY; ELECTRON MICROSCOPY; EX VIVO STUDY; FIBRIN POLYMERIZATION; HUMAN; MEDICAL RESEARCH; NONHUMAN; PRIORITY JOURNAL; SHEEP; SPECIES COMPARISON; SWINE;

EID: 14844364977     PISSN: 10510443     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.RVI.0000148828.40438.D3     Document Type: Article

References (29)

1. Marder VJ, Landskroner K, Novokhatny V, et al. Plasmin induces local thrombolysis without causing hemorrhage: a comparison with tissue plasminogen activator in the rabbit. Thromb Haemost 2001; 86:739-745.
2. Sabovic M, Lijnen HR, Keber D, Collen D. Effect of retraction on the lysis of human clots with fibrin specific and non-fibrin specific plasminogen activators. Thromb Haemost 1989; 62:1083-1087.
3. Novokhatny V, Taylor K, Zimmerman TP. Thrombolytic potency of acid-stabilized plasmin: superiority over tissue-type plasminogen activator in an in vitro model of catheter-assisted thrombolysis. J Thromb Haemost 2003; 1:1034-1041.
4. Stewart D, Kong M, Novokhatny V, Jesmok G, Marder VJ. Distinct dose-dependent effects of plasmin and TPA on coagulation and hemorrhage. Blood 2003; 101:3002-3007.
5. Winkler TA, Trerotola SO, Davidson DD, Milgrom ML. Study of thrombus from thrombosed hemodialysis access grafts. Radiology 1995; 197:461-465.
6. Valji K, Bookstein JJ, Roberts AC, Oglevie SB, Pittman C, O'Neill MP. Pulse-spray pharmacomechanical thrombolysis of thrombosed hemodialysis access grafts: long-term experience and comparison of original and current techniques. AJR Am J Roentgenol 1995; 164:1495-1500.
7. Bookstein JJ, Valji K. Pulse-spray pharmacomechanical thrombolysis. Cardiovasc Intervent Radiol 1992; 15:228-233.
8. Munster AM, Olsen AK, Bladbjerg EM. Usefulness of human coagulation and fibrinolysis assays in domestic pigs. Comp Med 2002; 52:39-43.
9. Blomback B. Fibrinogen structure, activation, polymerization and fibrin gel structure. Thromb Res 1994; 75:327-328.
10. Carr ME Jr, Alving BM. Effect of fibrin structure on plasmin-mediated dissolution of plasma clots. Blood Coagul Fibrinolysis 1995; 6:567-573.
11. Bajzar L, Manuel R, Nesheim ME. Purification and characterization of TAFI, a thrombin-activable fibrinolysis inhibitor. J Biol Chem 1995; 270:14477-14484.
12. Carr ME Jr, Gabriel DA, McDonagh J. Influence of factor XIII and fibronectin on fiber size and density in thrombin-induced fibrin gels. J Lab Clin Med 1987; 110:747-752.
13. Sadeghi S, Marder VJ, Stewart D, et al. Safety of plasmin in the setting of concomitant aspirin and heparin administration in an animal model of bleeding. J Thromb Haemost 2003; 1:2621-2625.
14. Collen D, Wiman B. Fast-acting plasmin inhibitor in human plasma. Blood 1978; 51:563-569.
15. Collen D, Wiman B. Turnover of antiplasmin, the fast-acting plasmin inhibitor of plasma. Blood 1979; 53:313-324.
16. Cynamon J, Lakritz PS, Wahl SI, Bakal CW, Sprayregen S. Hemodialysis graft declotting: description of the "lyse and wait" technique. J Vasc Interv Radiol 1997; 8:825-829.
17. Robbin ML, Oser RF, Allon M, et al. Hemodialysis access graft stenosis: US detection. Radiology 1998; 208:655-661.
18. Brattich M. Vascular access thrombosis: etiology and prevention. ANNA J 1999; 26:537-540.
19. Karges HE, Funk KA, Ronneberger H. Activity of coagulation and fibrinolysis parameters in animals. Arzneimittelforschung 1994; 44:793-797.
20. Jansen JW, Haverkate F, Koopman J, Nieuwenhuis HK, Kluft C, Boschman TA. Influence of factor XIIIa activity on human whole blood clot lysis in vitro. Thromb Haemost 1987; 57:171-175.
21. Francis CW, Marder VJ. Increased resistance to plasmic degradation of fibrin with highly crosslinked alpha-polymer chains formed at high factor XIII concentrations. Blood 1988; 71:1361-1365.
22. Leidy EM, Stern AM, Friedman PA, Bush LR. Enhanced thrombolysis by a factor XIIIa inhibitor in a rabbit model of femoral artery thrombosis. Thromb Res 1990; 59:15-26.
23. Wolberg AS, Monroe DM, Roberts HR, Hoffman M. Elevated prothrombin results in clots with an altered fiber structure: a possible mechanism of the increased thrombotic risk. Blood 2003; 101:3008-3013.
24. Wiman B, Collen D. On the mechanism of the reaction between human alpha 2-antiplasmin and plasmin. J Biol Chem 1979; 254:9291-9297.
25. Wiman B, Collen D. On the kinetics of the reaction between human antiplasmin and plasmin. Eur J Biochem 1978; 84:573-578.
26. Harpel PC. Alpha2-plasmin inhibitor and alpha2-macroglobulin-plasmin complexes in plasma. Quantitation by an enzyme-linked differential antibody immunosorbent assay. J Clin Invest 1981; 68:46-55.
27. Vogel PM, Bansal V, Marshall MW. Thrombosed hemodialysis grafts: lyse and wait with tissue plasminogen activator or urokinase compared to mechanical thrombolysis with the Arrow-Trerotola Percutaneous Thrombolytic Device. J Vasc Interv Radiol 2001; 12:1157-1165.
28. Bookstein JJ, Saldinger E. Accelerated thrombolysis. In vitro evaluation of agents and methods of administration. Invest Radiol 1985; 20:731-735.
29. Novokhatny VV, Jesmok GJ, Landskroner KA, Marder VJ, Zimmerman TP. Locally delivered plasmin: why should it be superior to plasminogen activators for direct thrombolysis? Trends Pharmacol Sci 2004; 25:72-75.